With these involvements of cMet in cancer progression and therapy, combination strategies using cMet inhibitors may bring beneficial effects for existing cancer therapies, not only by adding the effects of the monotherapy but also by preventing or reducing treatment resistance or inducing synergistic combination effects. The gene discussed is MET; the disease is cancer.